Previous 10 | Next 10 |
ROCKVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third quarter 2022 financial results after the close of the U.S. financial marke...
OpGen ( NASDAQ: OPGN ) said on Tuesday it had signed a collaboration agreement with Swiss pharma firm BioVersys AG for the use of its Unyvero platform in BioVersys’ Phase II clinical trial of drug candidate BV100. BV100 is an injectable formulation of rifa...
Unyvero platform for rapid diagnostics to be used in Phase II clinical trial of BV100 Focus on the detection of pneumonia patients infected with Acinetobacter baumannii ROCKVILLE, Md. and BASEL, Switzerland, Oct. 25, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN...
ROCKVILLE, Md., Oct. 03, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced that it has cl...
Prospective multicenter trial for the Unyvero UTI Panel has successfully completed enrollment of patient samples Urine samples have been collected from over 1,800 patients at 4 U.S. clinical trial sites Clinical performance evaluation aims at a subsequent FDA submission ...
OpGen ( NASDAQ: OPGN ) announced Friday it has signed a $3.38M securities purchase deal with a single institutional investor. It includes the the direct offering of 9,660,000 shares of OpGen ( OPGN ), 33,810 shares of its Series C mirroring preferred stock, and warrant...
ROCKVILLE, Md., Sept. 30, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced that it has e...
OpGen's ( NASDAQ: OPGN ) German subsidiary Curetis has signed an R&D collaboration agreement with global diagnostics alliance FIND. The collaboration is focused on demonstrating the capabilities of OpGen's Unyvero A30 RQ platform for use in low and middle income countr...
FIND, the global alliance for diagnostics, together with German KfW bank co-funds development of Unyvero A30 RQ platform for low and middle income countries (LMICs) Initial project focuses on feasibility study for the rapid detection of antimicrobial resistance (AMR) markers fro...
ROCKVILLE, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), today announced it will be featured as a presenting company at the H.C. Wainwright 24 th Annual Global Investment Conference. The conference is being held as a hybrid in-person and...
News, Short Squeeze, Breakout and More Instantly...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...